0RNK.LSE Inventiva S.A.

Healthcare Commercial Services & Supplies London Exchange
3.75 EUR
Close of Nov 3, 2026
2.58 6.19
Market cap
EUR 83.4M
P/E
-
P/B
-
ROE
-470.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is 0RNK.LSE undervalued?

Graham number

The Graham number of Inventiva S.A. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Inventiva S.A. fundamental analysis

No fundamental analysis for Inventiva S.A. yet.

Inventiva S.A. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Inventiva S.A.

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharido…

Full company profile